TristelTSNLF +6.35%96 EV-to-FCF is 19.78 as of Jun. 30, 2026, which is 43% below its 10-year median of 34.43. GuruFocus rates TSNLF with a GF Score™ of 96/100 and a GF Value™ of $6.94 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 419 Medical Devices & Instruments companies, Tristel ranks better than 54.65% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Tristel's Enterprise Value is $240.42 Mil.
Tristel's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $12.15 Mil. Therefore, Tristel's EV-to-FCF for today is 19.78.
The historical rank and industry rank for Tristel's EV-to-FCF or its related term are showing as below:
TSNLF'
s EV-to-FCF Range Over the Past 10 Years
Min: 9.52 Med: 34.43 Max: 69.1
Current: 20.24
During the past 13 years, the highest EV-to-FCF of Tristel was 69.10. The lowest was 9.52. And the median was 34.43.
TSNLF's EV-to-FCF is ranked better than 54.65% of 419
companies
in the Medical Devices & Instruments industry
Industry Median: 22.57
vs TSNLF: 20.24
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Tristel's share price for today is $5.53.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Tristel's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.219.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Tristel EV-to-FCF Related Terms
Tristel EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Tristel's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Tristel's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tristel EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Tristel's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Tristel's EV-to-FCF falls into.
Tristel's current Enterprise Value is $240.42 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Tristel's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $12.15 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tristel (TSNLF) has a EV-to-FCF of 19.78 as of Jun. 30, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Tristel and its competitors. This is 43% below median its historical median of 34.43. Over the past decade, Tristel's EV-to-FCF has ranged from 9.52 to 69.10. According to the industry distribution chart, Tristel ranks #190 out of 419 companies in the Medical Devices & Instruments industry, placing it in the top 45.3%.
Is Tristel's EV-to-FCF too high?
Tristel's current EV-to-FCF of 19.78 is 43% below median its 10-year median of 34.43. Over the past 10 years, this metric has ranged from a low of 9.52 to a high of 69.10. The Medical Devices & Instruments industry median EV-to-FCF is 22.57. Tristel's value of 19.78 is 12.4% below this industry median. Based on the distribution chart, Tristel ranks #190 out of 419 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Tristel has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Tristel's EV-to-FCF compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Tristel ranks #190 out of 419 companies for EV-to-FCF. This puts Tristel in the upper half of its industry. The industry median EV-to-FCF is 22.57. Tristel's value of 19.78 is 12.4% below this benchmark. Historically, Tristel's own EV-to-FCF has ranged from 9.52 to 69.10 over the past decade. While the company's 10-year median is 34.43 vs. the industry median of 22.57, Tristel has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 22.57, based on 419 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tristel's current EV-to-FCF of 19.78 is 12.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Tristel and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 22.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tristel's current EV-to-FCF is 19.78, which is 43% below median its own 10-year median of 34.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tristel stock overvalued right now?
Based on GuruFocus' analysis, Tristel (TSNLF) is currently considered Modestly Undervalued. The stock's GF Value™ is $6.94, compared to a current price of $5.53 — trading 20.3% below its estimated fair value. The current EV-to-FCF is 19.78, which is 43% below median its 10-year median of 34.43 and 12.4% below the Medical Devices & Instruments industry median of 22.57. Tristel's overall GF Score™ is 96/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Tristel (TSNLF), the current EV-to-FCF is 19.78 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tristel (TSNLF) Overvalued in 2026?
Based on GuruFocus' analysis, Tristel stock appears to be undervalued.
The current stock price of $5.53 is trading 20.3% below its estimated GF Value™ of $6.94.
GuruFocus considers Tristel to be Modestly Undervalued.
Key valuation signals for TSNLF:
EV-to-FCF: 19.78 (43% below median its 10-year median of 34.43)
GF Value™: $6.94 vs. price of $5.53 (20.3% below fair value)
Industry Position: 12.4% below the Medical Devices & Instruments median (#190 of 419)
No single metric tells the full story. See the TSNLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tristel PLC's business is the sale to hospitals of its proprietary chlorine dioxide chemistry used for the decontamination of medical devices under the Tristel brand and for the sporicidal disinfection of environmental surfaces under the Cache brand. Its operating segments include hospital medical device decontamination products used predominantly for infection control in hospitals; the manufacture and sale of hospital environmental surface disinfection products; and pharmaceutical and personal care product manufacturing industries, veterinary and animal welfare. The company generates the majority of its revenue from hospital medical device decontamination and operates geographically in the UK and overseas markets.
96GF Score
Get the complete analysis for TSNLF
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSNLF has been successfully added to your 
